FOUNDER, CHAIRMAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER

Mr. Gerrans served as the Founder, Chairman, President and Chief Executive Officer of Sanovas, Inc. and its 28 Subsidiary Corporations, which he also founded and assigned his Patents and Trademarks to, through December 31, 2018. Mr. Gerrans structured his Intellectual Properties under the corporate umbrella of his Life Science Accelerator to ensure the success of his Social Finance and Equity Crowd Funding Models. Doing so maximized the potentials for his Shareholders Returns on their Investment and mitigated his Shareholders Risk. 

Mr. Gerrans Achievements are listed, in part, as follows:

Conceived, Wrote and Assigned over 250 Multi-National Patents to his Life Science Accelerator, Sanovas, Inc

Wrote and lobbied for passage of Financial Legislation (JOBS Act, et al) to Legalize Social Finance and Equity Crowd Funding

Wrote and lobbied for passage of Disease Legislation intended to re-allocate and increase Lung Cancer research monies and the designation of MediCare Reimbursement for the early detection of Lung Cancer via Low Dose Helical CT

 Applied and created technological advances in digital automation to reform the legacy institutions on Wall Street and transform innovation capital

Raised over $70 Million via his Equity Crowd Funding Model

Negotiated $155 Million in Economic Development Matching Funds Grants

Qualified Life Science Accelerator Model for $150 Million in EB-5 Economic Development Funds Grants

Created 35 Breakthrough Medical Procedures featuring 389 unique Products and Drug Delivery technologies intended to cure Patients in a Single Treatment

Created 28 Companies to commercialize the 35+ Procedures and 389+ Products he invented. See "Companies"

Created Global Financial Planning and Analysis by Procedure(s)/Disease State(s) and obtained independent, third-party Valuations for 18 Companies 

Created Innovation Center and Venture Capital Fund at the Suzhou Institute for Nano-technology and Nano-bionics (SINANO)

Created Joint Venture and Patent License with Mayo Clinic to treat and cure Asthma via Bronchial Smooth Muscle Denervation

Created Joint Venture and Patent License with Stanford Scientists to create BioMolecular Imaging to Treat and cure Cancer

Created Joint Venture with Clinicians and Scientists from Harvard to detect Diabetic Retinopathy and cure Blindness in Diabetics

Created Joint Venture and Patent License with the University of Saskatchewan to detect Colon Cancer

Created Joint Venture with the Second Military Hospital of China to cure High Blood Pressure via Renal Denervation

Created Joint Venture with UCLA to create Medical Device Inspection and Sterilization System to cure device related infections and deaths

Earned $1.34 Billion Dollar Valuation, as of January 2018, for Sanovas, Inc. and Valuations for 17 Portfolio Companies in his Life Science Accelerator

Earned 2012 Frost & Sullivan Best Practices Award for New Product Innovation in Pulmonary Disease Treatment

Earned 2014 Frost & Sullivan Best Practices Award for New Product Innovation in Global Endoscopic Imaging 

Earned 2015 "Top 50" Global Start-Up Award

Earned 2016 "Top 10" Fastest Growing HealthCare Solutions Provider Award

Earned 2016 "Top 10" Most Promising Medical Imaging Solutions Provider Award

Earned 2017 "Top 20" Leading Healthcare Solutions Provider Award

Recognized as among "The 20 Most Influential Leaders in Healthcare in 2018"

Recognized as among "The 10 Most Transformational Leaders in Healthcare" in 2018